BlackRock’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,538,770
| Closed | -$259M | – | 5565 |
|
|
2023
Q2 | $259M | Buy |
2,538,770
+329,021
| +15% | +$31.1M | 0.01% | 1403 |
|
|
2023
Q1 | $201M | Sell |
2,209,749
-292,209
| -12% | -$17.1M | 0.01% | 1526 |
|
|
2022
Q4 | $95M | Buy |
2,501,958
+6,587
| +0.3% | +$227K | ﹤0.01% | 2031 |
|
|
2022
Q3 | $62.7M | Buy |
2,495,371
+335,724
| +16% | +$9.3M | ﹤0.01% | 2279 |
|
|
2022
Q2 | $65.6M | Buy |
2,159,647
+83,887
| +4% | +$2.5M | ﹤0.01% | 2303 |
|
|
2022
Q1 | $68M | Sell |
2,075,760
-38,290
| -2% | -$1.14M | ﹤0.01% | 2384 |
|
|
2021
Q4 | $55.7M | Sell |
2,114,050
-6,672
| -0.3% | -$516K | ﹤0.01% | 2589 |
|
|
2021
Q3 | $213M | Sell |
2,120,722
-15,049
| -0.7% | -$1.76M | 0.01% | 1666 |
|
|
2021
Q2 | $302M | Buy |
2,135,771
+651,773
| +44% | +$73.6M | 0.01% | 1465 |
|
|
2021
Q1 | $148M | Buy |
1,483,998
+68,485
| +5% | +$7.99M | ﹤0.01% | 1936 |
|
|
2020
Q4 | $175M | Buy |
1,415,513
+39,429
| +3% | +$5.18M | 0.01% | 1718 |
|
|
2020
Q3 | $134M | Sell |
1,376,084
-230,646
| -14% | -$28.8M | ﹤0.01% | 1697 |
|
|
2020
Q2 | $251M | Sell |
1,606,730
-516,649
| -24% | -$78.5M | 0.01% | 1198 |
|
|
2020
Q1 | $306M | Sell |
2,123,379
-120,492
| -5% | -$23.3M | 0.02% | 877 |
|
|
2019
Q4 | $459M | Buy |
2,243,871
+288,641
| +15% | +$52.7M | 0.02% | 853 |
|
|
2019
Q3 | $157M | Buy |
1,955,230
+39,523
| +2% | +$3.35M | 0.01% | 1589 |
|
|
2019
Q2 | $181M | Buy |
1,915,707
+58,853
| +3% | +$5.08M | 0.01% | 1510 |
|
|
2019
Q1 | $159M | Sell |
1,856,854
-101,310
| -5% | -$8.41M | 0.01% | 1574 |
|
|
2018
Q4 | $110M | Buy |
1,958,164
+29,802
| +2% | +$1.82M | 0.01% | 1723 |
|
|
2018
Q3 | $158M | Buy |
1,928,362
+424,582
| +28% | +$29.9M | 0.01% | 1649 |
|
|
2018
Q2 | $52.6M | Buy |
1,503,780
+311,924
| +26% | +$9.5M | ﹤0.01% | 2334 |
|
|
2018
Q1 | $24.4M | Sell |
1,191,856
-12,137
| -1% | -$312K | ﹤0.01% | 2655 |
|
|
2017
Q4 | $34.1M | Buy |
1,203,993
+307,636
| +34% | +$8.58M | ﹤0.01% | 2493 |
|
|
2017
Q3 | $27.9M | Buy |
896,357
+437,874
| +96% | +$13.2M | ﹤0.01% | 2616 |
|
|
2017
Q2 | $14.5M | Buy |
458,483
+105,466
| +30% | +$2.59M | ﹤0.01% | 2968 |
|
|
2017
Q1 | $8M | Buy |
353,017
+352,799
| +161,834% | +$8.71M | ﹤0.01% | 3209 |
|
|
2016
Q4 | $5K | Hold |
218
| – | – | ﹤0.01% | 3530 |
|
|
2016
Q3 | $6K | Sell |
218
-3,659
| -94% | -$72.6K | ﹤0.01% | 3490 |
|
|
2016
Q2 | $77K | Buy |
+3,877
| New | +$75.4K | ﹤0.01% | 2699 |
|
Other funds holding RETA
BlackRock's RETA Position: Q3 2023 in Review
BlackRock sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,538,770 shares — an estimated $259M sold.
BlackRock first reported a position in RETA in Q2 2016 and held it in 29 quarters. The position peaked at $459M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- BlackRock reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- BlackRock sold 2,538,770 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $259M.
- BlackRock first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2016 and held it in 29 quarters.
- BlackRock's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $459M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.